Precigen price to sales ratio PGEN

Market value divided by revenue over the last twelve months, since 2014.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 16.1×; Mar 2024
10-year median: 8.6×
10-year range: 2.3× to 20.9×
Peer median: 2.0×

Precigen's price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Mar 2024, at 16.1×.

On the days it had one over the last ten years, its median was 8.6×, from 2.3× in May 2022 to 20.9× in Sep 2023.

Price to sales ratio over time

median 8.6×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2024	16.1×	14.4×	19.7×
2023	15.1×	3.2×	20.9×
2022	4.2×	2.3×	7.1×
2021	7.7×	7.7×	18.7×
2020	20.5×	3.8×	20.5×
2019	7.4×	4.1×	8.6×
2018	4.8×	4.8×	11.3×
2017	6.9×	6.9×	16.6×
2016	15.3×	15.3×	25.4×
2015	21.3×	21.1×	83.5×
2014	53.1×	46.9×	92.2×

Against its peers

Companies in Drug Manufacturers - General nearest Precigen's size, closest first, today.

Company	Price to sales ratio
PGENPrecigen	n/m
PBHPrestige Consumer Healthcare	2.0×
HRMYHarmony Biosciences	2.2×
NRIXNurix Therapeutics	3.9×
ANIPANI Pharmaceuticals	1.7×
PAHCPhibro Animal Health	1.0×
ANABAnaptysbio	n/m
PCRXPacira BioSciences	1.9×
OGNOrganon	0.6×
LQDALiquidia	8.5×
ARQTArcutis Biotherapeutics	8.5×
Peer median	2.0×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Precigen

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.